Halozyme Therapeutics (NASDAQ:HALO) just reported results for the second quarter of 2024.
- Halozyme Therapeutics reported earnings per share of 91 cents. This was above the analyst estimate for EPS of 78 cents.
- The company reported revenue of $231.35 million.
- This was 10.73% better than the analyst estimate for revenue of $208.94 million.